세계의 암 방사선 치료 기기 시장 규모는 2024-2030년의 예측 기간에 CAGR로 7.78%의 성장이 전망됩니다. 시장은 다양한 유형의 암 환자 증가 시장 진출기업의 혁신적인 제품 포트폴리오 도입, 조기 발견에 대한 인식 증가 등으로 크게 성장하고 있으며, 이는 2024-2030년의 예측 기간 중 전체 시장 성장을 가속화할 것으로 예상됩니다.
암 방사선 치료 기기 시장 역학
세계보건기구(WHO)가 제공한 자료에 따르면 국제암연구소(IARC)는 2022년 전 세계에서 2,000만 건의 암이 새로 등록되었다고 밝혔습니다. 자료에 따르면 신규 등록 암 환자 중 폐암은 전 세계에서 250만 명의 신규 환자를 차지하며 가장 많은 암으로 나타났습니다. 이어 유방암 230만 명, 대장암 190만 명, 위암 97만 명 순이었습니다.
Global Cancer Observatory(2024년)는 2030년까지 새로 발생하는 암 환자는 전 세계에서 2,000만-2,410만 명에 달할 것으로 추정하고 있습니다. 지역별로는 아시아가 982만 6,539명, 유럽이 447만 1,422명, LAC가 155만 1,060명, 아프리카가 118만 5,216명입니다.
다양한 암 진단을 받는 환자가 증가함에 따라 의료 시스템은 효과적인 치료 옵션을 제공하기 위해 첨단 방사선 치료 기술을 도입할 수밖에 없습니다. 이러한 환자 수 증가는 방사선 종양학 인프라와 혁신적인 장비에 대한 투자를 더욱 촉진하여 시장 성장을 촉진하고 있습니다.
시장 주요 기업의 제품 개발 활동이 활발해짐에 따라 암 방사선 치료 기기 시장 성장으로 이어질 것으로 보입니다. 예를 들어 GE헬스케어는 2024년 5월 유럽치료방사선종양학회(European Society for Therapeutic Radiology and Oncology, ESTRO) 2024에서 새로운 Revolution RT 방사선 치료 CT 시스템을 발표했습니다. 공급업체에 따르면 이 새로운 시스템은 와이드 보어 CT 플랫폼으로 설계되었으며, Spectronic MRI Planner와의 인터페이스인 iRT(Intelligent Radiation Therapy) 플랫폼의 AI 강화 버전이 포함되어 있다고 합니다.
따라서 위의 모든 요인의 상호 작용은 2024-2030년의 예측 기간 중 암 방사선 치료 기기 시장을 촉진할 것으로 예상됩니다.
그러나 방사선에 따른 위험 요소와 대체 치료법의 가용성 등이 암 방사선 치료 기기 시장의 성장을 억제할 수 있습니다.
암 방사선 치료 기기 시장 부문별 분석
암 방사선 치료 기기 시장의 유형 부문에서는 정위적 첨단 전자/코발트 60 선형 가속기 감마나이프 하위 카테고리가 2023년 큰 매출 점유율을 차지할 것으로 예상됩니다. 이는 감마나이프가 널리 사용되고 있으며 다양한 유형의 만성질환의 관리를 강화하는 다양한 이점이 있기 때문입니다.
감마나이프는 다양한 각도에서 여러 개의 방사선 빔을 뇌의 특정 부위에 조사하는 기술입니다. 각 빔은 건강한 조직을 손상시키기에는 너무 약하므로 그 자체로 통과하여 해를 끼치지 않습니다. 감마나이프는 또한 건강한 주변 조직과 구조에 대한 손상을 전혀 또는 최소한으로 줄이면서 강력한 선량의 방사선을 조사할 수 있으며, 출혈, 감염, 뇌척수액 누출과 같은 합병증이 적습니다. 또 다른 장점은 전신 마취가 필요하지 않기 때문에 잠재적인 부작용이 없고, 단 한 번의 치료로 충분하다는 것입니다.
또한 여러 시장 기업이 강력한 포트폴리오를 보유하고 있으며, Leksell과 같은 주요 기업은 GammaKnife(R) Icon(TM), Leksell Gamma Knife(R) Lightning, Leksell Gamma Knife(R) Perfexion(TM) 등 다양한 감마나이프 제품을 제공합니다.(TM) 등 다양한 감마나이프 제품을 제공합니다.
따라서 감마나이프의 광범위한 적용과 다양한 장점은 성능과 사용 편의성을 향상시켜 2024-2030년의 예측 기간 중 전체 암 방사선 치료 기기 시장의 성장에 큰 영향을 미칠 것으로 예상됩니다.
세계의 암 방사선 치료 기기 시장에 대해 조사분석했으며, 각 지역의 시장 규모와 예측, 과거 3년 제품/기술개발, 시장의 주요 기업, 향후 기회등의 정보를 제공하고 있습니다.
Radiotherapy/Radiation Oncology Devices Market by Type (External Beam Radiation Therapy [Linear Accelerators (Linac), Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators [Gamma Knife, CyberKnife, and TomoTherapy], Proton Therapy, Cyclotron, Synchrotron, and Others], and Internal Beam Radiotherapy/Brachytherapy), Technology (External Beam Radiation Therapy [Image-Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Technology, Proton Beam Therapy, 3D Conformal Radiotherapy (3D CRT), and Others] and Internal Beam Radiotherapy/Brachytherapy [Low-Dose Rate Brachytherapy and High-Dose Rate Brachytherapy], Application (External Beam Radiation Therapy [Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, and Others] and Internal Beam Radiation Therapy [Prostate Cancer, Gynecological Cancer, Breast Cancer, Cervical Cancer, Penile Cancer, and Others], End-User (Hospitals, Independent Radiotherapy Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing instances of cancer and the rising product developmental activities worldwide
The radiotherapy/radiation oncology devices market is projected to grow at a 7.78% CAGR during the forecast period from 2024 to 2030. The radiotherapy/radiation oncology devices market is growing significantly due to the increasing cases of different types of cancers among the population, the introduction of innovative product portfolios by market players, and the growing awareness for early detection are factors that are expected to escalate the overall growth of the radiotherapy/radiation oncology devices market during the forecast period from 2024 to 2030.
Radiotherapy/Radiation Oncology Devices Market Dynamics:
According to data provided by the World Health Organization in 2024, the International Agency for Research on Cancer (IARC) stated that 20 million new instances of cancer were registered in 2022 globally. As per the same source, lung cancer accounted for 2.5 million new cases globally, of all the registered new cancer cases, making it the most common cancer. Next in order of incidence was breast cancer with 2.3 million cases, colon cancer with 1.9 million cases, and stomach cancer with 0.97 million cases globally.
The Global Cancer Observatory (2024), estimated that the new instances of cancer globally would reach from 20 million to 24.1 million by the year 2030. It stated that Asia accounted for 9,826,539 cancer cases, Europe accounted for 4,471,422 cancer cases, LAC accounted for 1,551,060 cancer cases, and Africa accounted for 1,185,216 cancer cases.
As more patients are diagnosed with various cancers, healthcare systems are compelled to adopt advanced radiotherapy technologies to provide effective treatment options. This growing patient population is further driving investments in radiation oncology infrastructure and innovative devices and thereby boosting the market for same.
Increased product developmental activities by market key players is slated to witness market growth for radiotherapy/radiation oncology devices. For example, in May 2024, GE HealthCare unveiled its new Revolution RT radiation therapy CT system at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2024. The new system was designed with a wide-bore CT platform and includes an updated AI-enhanced version of the Intelligent Radiation Therapy (iRT) platform, which interfaces with the Spectronic MRI Planner, according to the vendor.
Hence, the interplay of all the above-mentioned factors are expected to drive the market for radiotherapy/radiation oncology devices market during the given forecast period from 2024 to 2030.
However, risk factors associated with radiation, and the availability of alternative therapies, among others may restrict the market growth of radiotherapy/radiation oncology devices.
Radiotherapy/Radiation Oncology Devices Market Segment Analysis:
Radiotherapy/Radiation Oncology Devices Market by Type (External Beam Radiation Therapy [Linear Accelerators (Linac), Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators [Gamma Knife, CyberKnife, and TomoTherapy], Proton Therapy, Cyclotron, Synchrotron, and Others], and Internal Beam Radiotherapy/Brachytherapy), Technology (External Beam Radiation Therapy [Image-Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Technology, Proton Beam Therapy, 3D Conformal Radiotherapy (3D CRT), and Others] and Internal Beam Radiotherapy/Brachytherapy [Low-Dose Rate Brachytherapy and High-Dose Rate Brachytherapy], Application (External Beam Radiation Therapy [Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, and Others] and Internal Beam Radiation Therapy [Prostate Cancer, Gynecological Cancer, Breast Cancer, Cervical Cancer, Penile Cancer, and Others], End-User (Hospitals, Independent Radiotherapy Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the type segment of the radiotherapy/radiation oncology devices market, the gamma knife sub- category of stereotactic advanced electron/cobalt-60 linear accelerators is expected to have a significant revenue share in the year 2023. This is because of the widespread uses and various advantages of gamma knife that enhance the management of different type of chronic conditions.
Gama knife is a technique that uses numerous beams of radiation from various angles to target a specific area of the brain. Since each beam is too weak to harm the healthy tissue, it passes through on its own and is less harmful. Gamma knife also allows a powerful dose of radiation to be delivered with no or minimal damage to healthy surrounding tissue and structures and results in fewer complications such as bleeding, infection, or cerebrospinal fluid leakage. Another added advantage is that it requires no general anesthesia, eliminating the related potential side effects, and is performed in a single session, often on an outpatient basis and only occasionally requiring an overnight stay.
Moreover, several market players have a strong portfolio and key players like Leksell has a broad range of GammaKnife product offerings, some of them are Gamma Knife(R) Icon(TM), Leksell Gamma Knife(R) Lightning, Leksell Gamma Knife(R) Perfexion(TM), are now actively being involved to develop radiotherapy/radiation oncology devices.
Therefore, the widespread uses and various advantages of gamma knives enhance performance and usability, solidifying the significant impact on the growth of the overall radiotherapy/radiation oncology devices market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall radiotherapy/radiation oncology devices market:
Among all the regions, North America is estimated to hold a significant revenue share in the radiotherapy/radiation oncology devices market. This can be attributed to several factors such as rising cancer cases, supportive government policies in increasing focus promoting oncology research, combined with significant advancements in product development and regulatory approvals are acting as key factors that contribute to the growth of the radiotherapy/radiation oncology devices market in the North America region during the forecast period from 2024 to 2030.
National Cancer Institute (2024) estimated that 2 million new cases of cancer will be diagnosed in the US by the end of 2024. Furthermore, it is estimated that prostate, lung, and colorectal cancers are expected to represent approximately 48% of all cancer diagnoses in men. For women, the most prevalent cancers are breast, lung, and colorectal, which are expected to account for about 51% of all new cancer diagnoses.
According to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases and Canada represented 10.9% of all cancer cases in the region.
With the US expected to account for a substantial proportion of these cancer cases, healthcare providers are compelled to enhance their cancer treatment capabilities, leading to greater investment in advanced radiation therapies. This growing patient population necessitates innovative and effective treatment options, thereby expanding the market for the same.
The US Food and Drug Administration also provides a supportive environment for newer technologies to reach the market with the provision of "breakthrough device" designation to emerging technologies and products in the medical devices domain. For instance, in February 2022, GenesisCare announced that it enrolled the first patients in a trial for Boston Scientific's SpaceOAR Vue hydrogel. Boston Scientific's SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT).
The increased emphasis on product development activities and the high interest of device manufacturers in accessing local markets further aid in the growth of the regional markets for radiotherapy/radiation oncology devices. For instance, in October 2021, the US Food and Drug Administration (FDA) granted breakthrough device designation to Alpha Tau's alpha-radiation cancer therapy to treat patients suffering from recurrent glioblastoma multiforme (GBM).
Therefore, the interplay of all the factors mentioned above would provide a conducive growth environment for the North America region in the radiotherapy/radiation oncology devices market during the forecast period from 2024 to 2030.
Radiotherapy/Radiation Oncology Devices Market key players:
Some the key market players operating in the radiotherapy/radiation oncology devices market include Siemens Healthineers AG, Elekta AB, Accuray Incorporated, BA Worldwide, BD, Isoray Inc., Mevion Medical Systems, Viewray Technologies, Inc., Eckert & Ziegler BEBIG, ZEISS, GT Medical Technologies, Inc., Hitachi, Ltd., iCAD, Inc., IntraOp Medical, Inc., Panacea Medical Technologies Pvt. Ltd., SIT - S.I.T. Sordina IORT Technologies S.p.A., Sensus Healthcare, Inc., Theragenics, Optivus Proton Therapy, Inc., P-cure, and others.
Recent Developmental Activities in the Radiotherapy/Radiation Oncology Devices Market:
Key takeaways from the Radiotherapy/Radiation Oncology Devices market report study
Target audience who can be benefited from this Radiotherapy/Radiation Oncology Devices market report study
Frequently Asked Questions for the Radiotherapy/Radiation Oncology Devices Market: